Healthcare · Drug Manufacturers - Specialty & Generic
Price
$2.42
Market Cap
$1.9M
Employees
75
Beta
1.89
Avg Volume
84,796
CEO
Feng Zhou
Business Description
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company serves pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Taizhou, China.
Business History
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-0.30
Stock Price: $2.42
EPS (Diluted): -8.18
EPS (Diluted): -8.18
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
0.07
Stock Price: $2.42
Total Equity: $15.44M
Shares: 403,920
Total Equity: $15.44M
Shares: 403,920
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
6.24
Market Cap: $1.87M
Total Debt: $807,229
Cash: $18.10M
EBITDA: -$2.57M
Total Debt: $807,229
Cash: $18.10M
EBITDA: -$2.57M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
-$16.0M
Market Cap: $1.87M
Total Debt: $807,229
Cash: $18.10M
Total Debt: $807,229
Cash: $18.10M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.61
Stock Price: $2.42
Revenue: $1.74M
Shares: 403,920
Revenue: $1.74M
Shares: 403,920
EV/Sales (Total value vs revenue — works when P/E can't)
API-9.22
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
21.1%
Gross Profit: $367,427
Revenue: $1.74M
Revenue: $1.74M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-154.0%
Operating Income: -$2.68M
Revenue: $1.74M
Revenue: $1.74M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-189.8%
Net Income: -$3.30M
Revenue: $1.74M
Revenue: $1.74M
ROE (Profit from shareholder equity)
CALCNet Income / Total Equity
-21.4%
Net Income: -$3.30M
Total Equity: $15.44M
Total Equity: $15.44M
ROIC (Profit from all invested capital)
CALCNOPAT / Invested Capital
144.7%
Operating Income: -$2.68M
Tax Rate: 0.0%
Equity: $15.44M
Total Debt: $807,229
Cash: $18.10M
Tax Rate: 0.0%
Equity: $15.44M
Total Debt: $807,229
Cash: $18.10M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
3.54
Current Assets: $21.30M
Current Liabilities: $6.01M
Current Liabilities: $6.01M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.05
Short-Term Debt: $710,965
Long-Term Debt: $96,264
Total Debt: $807,229
Total Equity: $15.44M
Long-Term Debt: $96,264
Total Debt: $807,229
Total Equity: $15.44M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$4.31
Revenue: $1.74M
Shares: 403,920
Shares: 403,920
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$38.22
Total Equity: $15.44M
Shares: 403,920
Shares: 403,920
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-5.81
Operating CF: -$2.35M
CapEx: -$2,023
Shares: 403,920
CapEx: -$2,023
Shares: 403,920
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $2.42
Stock Price: $2.42
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$3.30M
Net Income: -$3.30M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares SXTC against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 23, 2026 2:32am (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $4.8M | $2.6M | $2.0M | $1.9M | $1.7M |
| Cost of Revenue | $1.9M | $1.4M | $1.5M | $1.4M | $1.4M |
| Gross Profit | $2.8M | $1.3M | $426,271 | $553,971 | $367,427 |
| Operating Expenses | $5.0M | $6.4M | $6.0M | $3.1M | $3.0M |
| Operating Income | -$2.2M | -$5.2M | -$5.6M | -$2.5M | -$2.7M |
| Net Income | -$2.7M | -$5.7M | -$5.9M | -$3.1M | -$3.3M |
| EBITDA | -$1.9M | -$5.1M | -$5.2M | -$2.4M | -$2.6M |
| EPS | $-95.48 | $-137.92 | $-22.23 | $-3.57 | $-8.18 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 23, 2026 2:32am (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $13.3M | $15.5M | $17.4M | $12.1M | $18.1M |
| Total Current Assets | $23.2M | $22.5M | $19.5M | $14.2M | $21.3M |
| Total Assets | $34.5M | $33.5M | $29.6M | $23.1M | $21.7M |
| Current Liabilities | $18.6M | $17.1M | $14.5M | $8.9M | $6.0M |
| Long-Term Debt | $6,292 | $0 | $117,862 | $117,129 | $96,264 |
| Total Liabilities | $18.6M | $17.1M | $14.9M | $9.2M | $6.2M |
| Total Equity | $16.0M | $16.4M | $14.7M | $13.9M | $15.4M |
| Retained Earnings | -$10.0M | -$15.7M | -$21.6M | -$24.7M | -$28.0M |
Cash Flow (Annual)
Last updated: Jun 23, 2026 2:32am (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$1.3M | $268,293 | $-80,757 | -$1.9M | -$2.3M |
| Capital Expenditure | $-93,044 | $-62,490 | $-70,684 | $-7,063 | $-2,023 |
| Free Cash Flow | -$1.4M | $205,803 | $-151,441 | -$1.9M | -$2.3M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $6.1M | $2.2M | $1.8M | -$5.3M | $6.1M |
Growth Trends (YoY %)
Last updated: Jun 23, 2026 2:32am (4d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -45.5% | -24.2% | -2.2% | -9.7% |
| Gross Profit Growth | -55.9% | -65.9% | +30.0% | -33.7% |
| Operating Income Growth | -136.2% | -8.1% | +55.1% | -6.6% |
| Net Income Growth | -108.7% | -3.5% | +47.8% | -6.6% |
| EBITDA Growth | -172.8% | -3.1% | +54.9% | -9.4% |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for SXTC — it's generated by the pipeline (
market-narrative step).
No community reviews yet for SXTC.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30